MA39809B1 - Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih - Google Patents

Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih

Info

Publication number
MA39809B1
MA39809B1 MA39809A MA39809A MA39809B1 MA 39809 B1 MA39809 B1 MA 39809B1 MA 39809 A MA39809 A MA 39809A MA 39809 A MA39809 A MA 39809A MA 39809 B1 MA39809 B1 MA 39809B1
Authority
MA
Morocco
Prior art keywords
reverse transcriptase
substituted nucleoside
nucleoside derivatives
hiv reverse
transcriptase inhibitors
Prior art date
Application number
MA39809A
Other languages
English (en)
Other versions
MA39809A (fr
Inventor
Vinay Girijavallabhan
David Olsen
Zhibo Zhang
Bing-Yu Tang
Jianmin Fu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39809(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA39809A publication Critical patent/MA39809A/fr
Publication of MA39809B1 publication Critical patent/MA39809B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés nucléosidiques 4'-substitués de formule i (formule i) et leur utilisation pour l'inhibition de la transcriptase inverse du vih, la prévention d'une infection par le vih, le traitement d'une infection par le vih et la prévention, le traitement et le retardement de l'apparition ou de la progression du sida et/ou du complexe lié au sida.
MA39809A 2014-03-28 2015-03-26 Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih MA39809B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (fr) 2014-03-28 2014-03-28 Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse
PCT/US2015/022621 WO2015148746A1 (fr) 2014-03-28 2015-03-26 Dérivés nucléosidiques 4'-substitués utilisés comme inhibiteurs de la transcriptase inverse du vih

Publications (2)

Publication Number Publication Date
MA39809A MA39809A (fr) 2021-04-07
MA39809B1 true MA39809B1 (fr) 2021-10-29

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39809A MA39809B1 (fr) 2014-03-28 2015-03-26 Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih

Country Status (42)

Country Link
US (2) US9777035B2 (fr)
EP (1) EP3122752B1 (fr)
JP (1) JP6182680B2 (fr)
KR (1) KR101961009B1 (fr)
CN (1) CN106795199B (fr)
AP (1) AP2016009482A0 (fr)
AR (2) AR099788A1 (fr)
AU (2) AU2015236018B2 (fr)
CA (1) CA2943792C (fr)
CL (1) CL2016002414A1 (fr)
CR (1) CR20160451A (fr)
CY (1) CY1124829T1 (fr)
DK (1) DK3122752T3 (fr)
DO (1) DOP2016000265A (fr)
EA (1) EA031476B1 (fr)
EC (1) ECSP16085206A (fr)
ES (1) ES2894228T3 (fr)
GE (2) GEAP201914307A (fr)
GT (1) GT201600201A (fr)
HR (1) HRP20211622T1 (fr)
HU (1) HUE056913T2 (fr)
IL (1) IL247923B (fr)
JO (1) JO3636B1 (fr)
LT (1) LT3122752T (fr)
MA (1) MA39809B1 (fr)
MD (1) MD4812C1 (fr)
MX (1) MX367058B (fr)
MY (1) MY194635A (fr)
NI (1) NI201600145A (fr)
NZ (1) NZ724343A (fr)
PE (1) PE20170197A1 (fr)
PH (1) PH12016501897B1 (fr)
PL (1) PL3122752T3 (fr)
PT (1) PT3122752T (fr)
RS (1) RS62418B1 (fr)
SG (1) SG11201608031PA (fr)
SI (1) SI3122752T1 (fr)
SV (1) SV2016005290A (fr)
TW (1) TWI660967B (fr)
UA (1) UA120758C2 (fr)
WO (2) WO2015143712A1 (fr)
ZA (1) ZA201606413B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
MX391226B (es) * 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
PT3523287T (pt) 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting
WO2018110591A1 (fr) * 2016-12-13 2018-06-21 ヤマサ醤油株式会社 Dérivé de 2'-désoxy-7-déazapurine nucléoside ayant une activité antivirale
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
CA3075950A1 (fr) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Nucleosides substitues, nucleotides et analogues de ceux-ci
EP3727401A4 (fr) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques utilisés comme agonistes sting
CN111971284A (zh) * 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
EP3762396A1 (fr) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Composés utiles dans la thérapie du vih
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
EP3774765A4 (fr) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting
JP7773906B2 (ja) 2018-07-09 2025-11-20 メルク・シャープ・アンド・ドーム・エルエルシー ４’－エチルヌクレオシド類似体の酵素的合成
AU2019317810A1 (en) * 2018-08-09 2021-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
EP3914604B1 (fr) 2019-01-25 2026-03-04 Brown University Compositions comprenant du censavudine ou de l'elvucitabine pour le traitement de l'inflammation et des troubles associés à l'âge
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
CA3146679A1 (fr) * 2019-07-27 2021-02-04 Brii Biosciences, Inc. Derive d'adenosine et composition pharmaceutique le comprenant
KR20220066303A (ko) * 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
WO2021188959A1 (fr) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
EP4192474B1 (fr) 2020-08-07 2025-09-10 Gilead Sciences, Inc. Promédicaments d'analogues nucléotidiques de phosphonamide et leur utilisation pharmaceutique
IL300453A (en) * 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2022074391A1 (fr) 2020-10-08 2022-04-14 Storm Therapeutics Limited Composés inhibiteurs de mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
EP4281081A4 (fr) * 2021-01-25 2025-05-14 Brii Biosciences, Inc. Dérivé d'adénosine et composition pharmaceutique le comprenant
EP4281083A4 (fr) 2021-01-25 2025-01-01 Brii Biosciences, Inc. Polythérapie contre le vih comprenant un dérivé d'adénosine et des inhibiteurs de capside
CA3216162A1 (fr) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Procedes de preparation de carbanucleosides a l'aide d'amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4389750A4 (fr) 2021-08-20 2025-10-01 Shionogi & Co Dérivés nucléosidiques et leurs promédicaments ayant une action inhibitrice de la croissance virale
EP4405357A1 (fr) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Analogues de ribonucléosides dirigés contre le sars-cov-2
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
EP4547665A1 (fr) * 2022-06-30 2025-05-07 Gilead Sciences, Inc. Formes solides d'un analogue nucléosidique et leurs utilisations
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CR20250310A (es) * 2023-01-30 2025-08-25 Merck Sharp & Dohme Llc Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'
EP4704831A2 (fr) * 2023-04-26 2026-03-11 Lakewood Amedex, Inc. Composés de pyrimidinone et d'azapyrimidinone substitués, compositions et utilisations associées
TW202517633A (zh) 2023-07-07 2025-05-01 美商默沙東有限責任公司 作為選擇性細胞毒性劑之四氫喹唑啉衍生物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR927003044A (ko) 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (fr) 2002-01-17 2003-07-31 Ribapharm Inc. Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
WO2003099840A1 (fr) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides a unites nucleosidiques modifiees
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
WO2005003047A1 (fr) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Vitre pouvant etre chauffee par une lumiere invisible
CA2502109C (fr) 2004-03-24 2010-02-23 Yamasa Corporation Derive de 2-haloadenosine avec substitution sur le carbone en position 4'
EP1987050A2 (fr) 2006-02-14 2008-11-05 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (fr) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Analogues nucléosidiques antiviraux
WO2010002877A2 (fr) 2008-07-03 2010-01-07 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JPWO2010027005A1 (ja) 2008-09-05 2012-02-02 壽製薬株式会社 置換アミン誘導体及びこれを有効成分とする医薬組成物
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
KR101445012B1 (ko) 2009-12-17 2014-09-26 머크 샤프 앤드 돔 코포레이션 Ｓｙｋ 억제제로서의 아미노피리미딘
MX2012013824A (es) 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
MD4496C1 (ro) * 2012-03-13 2018-02-28 Gilead Sciences, Inc. Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
IL247923A0 (en) 2016-11-30
AU2017225090A1 (en) 2017-09-28
ZA201606413B (en) 2018-04-25
MD20160117A2 (ro) 2017-02-28
JP2017512797A (ja) 2017-05-25
CA2943792C (fr) 2020-02-25
AU2017225090B2 (en) 2018-08-09
LT3122752T (lt) 2021-11-10
AR130699A2 (es) 2025-01-08
GT201600201A (es) 2018-12-18
IL247923B (en) 2021-01-31
DK3122752T3 (da) 2021-10-25
GEP20197009B (en) 2019-08-12
BR112016022438A2 (pt) 2017-08-15
BR112016022438A8 (pt) 2021-06-29
TW201619180A (zh) 2016-06-01
UA120758C2 (uk) 2020-02-10
SI3122752T1 (sl) 2021-11-30
PL3122752T3 (pl) 2022-01-03
MY194635A (en) 2022-12-08
PH12016501897A1 (en) 2016-12-19
PE20170197A1 (es) 2017-03-22
SG11201608031PA (en) 2016-10-28
KR101961009B1 (ko) 2019-03-21
MX2016012659A (es) 2016-12-14
HUE056913T2 (hu) 2022-03-28
AU2015236018B2 (en) 2017-09-28
US20180002366A1 (en) 2018-01-04
CR20160451A (es) 2016-12-06
KR20160128437A (ko) 2016-11-07
CA2943792A1 (fr) 2015-10-01
GEAP201914307A (en) 2019-04-10
MA39809A (fr) 2021-04-07
NZ724343A (en) 2020-02-28
ECSP16085206A (es) 2017-08-31
HRP20211622T1 (hr) 2022-03-04
DOP2016000265A (es) 2017-04-30
JO3636B1 (ar) 2020-08-27
EA201691931A1 (ru) 2017-02-28
US20150274767A1 (en) 2015-10-01
NI201600145A (es) 2016-10-27
MD4812B1 (ro) 2022-06-30
CN106795199B (zh) 2020-01-10
AR099788A1 (es) 2016-08-17
ES2894228T3 (es) 2022-02-14
AP2016009482A0 (en) 2016-10-31
RS62418B1 (sr) 2021-10-29
JP6182680B2 (ja) 2017-08-16
EP3122752A1 (fr) 2017-02-01
EP3122752B1 (fr) 2021-08-25
WO2015148746A1 (fr) 2015-10-01
PH12016501897B1 (en) 2023-08-02
SV2016005290A (es) 2018-05-03
US9777035B2 (en) 2017-10-03
AU2015236018A1 (en) 2016-10-06
CL2016002414A1 (es) 2017-05-05
MX367058B (es) 2019-08-02
WO2015143712A1 (fr) 2015-10-01
PT3122752T (pt) 2021-10-20
TWI660967B (zh) 2019-06-01
EA031476B1 (ru) 2019-01-31
MD4812C1 (ro) 2023-01-31
CN106795199A (zh) 2017-05-31
CY1124829T1 (el) 2022-11-25

Similar Documents

Publication Publication Date Title
MA39809B1 (fr) Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
ZA202003176B (en) Compounds useful as kinase inhibitors
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MX391226B (es) Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA44020B1 (fr) Composés antitumoraux
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
CA3010327A1 (fr) Pyrimidines a substitution aryle a utiliser dans une infection par le virus de la grippe
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
NZ747313A (en) Imidazolone compounds as human neutrophil elastase inhibitors
MA39305A3 (fr) Dérivés d'éthynyle
FR3058640B1 (fr) Composes pour leur utilisation dans le traitement de la grippe
EA201991735A1 (ru) Азолопиримидины для лечения раковых заболеваний
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств
MA44011B1 (fr) Méthodes de prévention et de traitement du vih et du sida